The antiserum was produced against synthesized peptide derived from human RelB around the phosphorylation site of Ser552. AA range:530-579

Phospho-RelB (S552) Polyclonal Antibody detects endogenous levels of RelB protein only when phosphorylated at S552.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):LLsPG

RELB

Transcription factor RelB

RELB ;
Transcription factor RelB ;
I-Rel

caution:Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B. ,domain:Both N- and C-terminal domains are required for transcriptional activation. ,function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation , immunity , differentiation , cell growth , tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65 , RELB , NFKB1/p105 , NFKB1/p50 , REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors , respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway , I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators , subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. ,induction:By mitogens. ,PTM:Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation. ,similarity:Contains 1 RHD (Rel-like) domain. ,subunit:Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50 , NFKB2/p52 and NFKB2/p100. Interacts with NFKBID. ,

Caution:Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B. ,Domain:Both N- and C-terminal domains are required for transcriptional activation. ,Function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation , immunity , differentiation , cell growth , tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65 , RELB , NFKB1/p105 , NFKB1/p50 , REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors , respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway , I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators , subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. ,induction:By mitogens. ,PTM:Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation. ,similarity:Contains 1 RHD (Rel-like) domain. ,subunit:Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50 , NFKB2/p52 and NFKB2/p100. Interacts with NFKBID. ,

Nucleus . Cytoplasm , cytoskeleton , microtubule organizing center , centrosome . Colocalizes with NEK6 in the centrosome.

>>MAPK signaling pathway ;
>>NF-kappa B signaling pathway ;
>>Osteoclast differentiation ;
>>C-type lectin receptor signaling pathway ;
>>Human T-cell leukemia virus 1 infection ;
>>Epstein-Barr virus infection